March is Bleeding Disorders Awareness Month. It is a time when organizations such as the National Hemophilia Foundation and the Hemophilia Federation of America encourage the community to share their stories about life with a bleeding disorder. Many use social media to spread awareness by posting…

Enzyre is partnering with Takeda with a goal of developing at-home assays to help people with monitoring congenital bleeding disorders, including hemophilia, and to diagnose these disorders. This partnership builds on an existing, 2019 research collaboration between these…

When my youngest son, Caeleb, was in elementary school, my main objective was to get him to school every day and not receive a phone call from the nurse. That may not sound like an accomplishment, as most people send their children to school regularly without issue, but complications…

When I was a child, I learned a song called “Greatest Love of All.” I’ve always found the first two lines particularly striking: “I believe the children are our future/ Teach them well and let them lead the way.” Now that I am a mom to my very own spunky…

The European Medicines Agency (EMA) has agreed to review an application by Laboratoire Francais du Fractionnement et des Biotechnologies, a French biopharmaceutical known as LFB, requesting the approval of eptacog beta for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors. A…

Activities are underway to mark Bleeding Disorders Awareness Month, set aside each March to call attention to such disorders as hemophilia and von Willebrand disease, and the more than three million U.S. residents living with them. Patients, caregivers, and activists nationwide are jumping on social media platforms, taking…

Back in Texas in good ol’ 1996, when my first son came into the world, a nice, well put-together doctor entered our room. He introduced himself as Dr. Connelly, the pediatrician on call. He appeared very polite and had an effortless bedside manner. He let us know that our…

Sanofi has reduced the dosing of its investigational treatment fitusiran in clinical trials to lower the risk of blood clots in people with hemophilia, according to a joint statement representing patient organizations worldwide. In October 2020, the company placed a voluntary dosing hold on its full clinical…

It just slipped out that one time. I wasn’t even thinking. My husband, Jared, and I had been talking casually about how some of his friends had taken up cycling, when I made the offhand comment that he might be able to do the same. After all, I said, other…

Owing to conflicting market exclusivity rights, the U.S. Food and Drug Administration (FDA) has partially rescinded its decision to approve BeneFIX and Ixinity for additional indications both therapies received last year for the treatment of hemophilia B, according to the National Hemophilia Foundation. Pfizer’s BeneFIX and…